Filing Details

Accession Number:
0001567619-18-002811
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-09-18 16:09:01
Reporting Period:
2018-09-14
Accepted Time:
2018-09-18 16:09:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1367644 Emergent Biosolutions Inc. EBS Pharmaceutical Preparations (2834) 141902018
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1380187 Daniel Abdun-Nabi 400 Professional Dr, Suite 400
Gaithersburg MD 20879
Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-09-14 28,220 $13.38 194,787 No 4 M Direct
Common Stock Disposition 2018-09-14 28,220 $65.00 166,567 No 4 S Direct
Common Stock Acquisiton 2018-09-17 1,319 $13.38 167,886 No 4 M Direct
Common Stock Disposition 2018-09-17 1,319 $65.00 166,567 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2018-09-14 28,220 $0.00 28,220 $13.38
Common Stock Stock Option (Right to Buy) Acquisiton 2018-09-17 1,319 $0.00 1,319 $13.38
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
1,319 2020-03-11 No 4 M Direct
0 2020-03-11 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 1,936 Indirect By Son
Footnotes
  1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi.
  2. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
  3. Consists of an option granted under the company's stock incentive plan as amended and restated.
  4. The option grant vested in three equal installments on the day prior to the first, second and third anniversary dates of the grant.